5-FLUORONICOTINIC ACID

Summary

5-Fluoronicotinic Acid (CHEMBL397783) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including laryngeal neoplasm and pharynx cancer.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 141.1 Da · C6H4FNO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL397783
Name	5-FLUORONICOTINIC ACID
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	120232
Molecular formula	C6H4FNO2
Molecular weight	141.1
InChIKey	BXZSBDDOYIWMGC-UHFFFAOYSA-N

SMILES: C1=C(C=NC=C1F)C(=O)O

IUPAC name: 5-fluoropyridine-3-carboxylic acid

Patent coverage: 125 distinct patent families (386 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 382 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Hydroxycarboxylic acid receptor 2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HCAR2	5.28	EC50	5300	nM	CHEMBL_ACT_2037692

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
laryngeal neoplasm	3	MONDO:0021071	EFO:0003817
pharynx cancer	3	MONDO:0005517	EFO:0005577

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00169182	PHASE3	COMPLETED	Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).